Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial
Authors' conclusion
In individuals with type 2 diabetes and CKD, LNS intake increases the risk of heart failure and cardiovascular death, while renal outcomes are unaffected by sodium intake. Canagliflozin mitigates the increased cardiovascular risk in individuals with LNS intake, while offering renal protection irrespective of dietary sodium.
Study context
- Population
- Individuals with T2D and chronic kidney disease (CKD) in the CREDENCE trial
- Participants
- 2,573 individuals
- Comparison
- Canagliflozin 100 mg vs placebo, by dietary sodium intake
- Low-normal sodium (LNS)n = 1,286
- High sodium (HS)n = 1,287reference
- Primary endpoint
- CV death or hospitalisation for HF
- Follow-up
- Median 2.6 years
Methodological detailspost hoc analysis
- Post hoc analysis
Primary result
As reported in the abstract
HF/CV death
Adjusted hazard ratio (95% CI)
LNSvs HSplacebo group
1.56(1.10–2.23)
Canagliflozinvs PlaceboLNS group
0.48(0.33–0.70)
Canagliflozinvs PlaceboHS group
1.05(0.73–1.53)
Further findings
HF alone
- Similar patterns were seen for HF alone
Composite renal outcome
- Sodium intake had no effect on renal outcomes; canagliflozin reduced renal risk in both LNS and HS
All-cause death
- Neither sodium intake nor canagliflozin influenced all-cause mortality
Original publication
Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial. Diabetologia. Published 12 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →